Ataluren Update - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Ataluren Update - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: The pivotal Phase 2b trial of ataluren, an investigational new drug being studied in nonsense mutation Duchenne/Becker muscular dystrophy (DBMD), was completed in late 2009. It had enrolled 174 patients at 37 trial sites in 11 countries on four continents. As PTC and statistics experts have analyzed the complex data from this trial using various statistical methods, the company has come to understand that the results are very promising.